STTK
Shattuck Labs, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Shattuck Labs, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
No thesis.
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Shattuck Labs, Inc.
4.50
−0.65 · −12.57%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Shattuck Labs, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Shattuck Labs, Inc..
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $93.2M | 15.89% | +36.16% |
| Adage Capital Partners GP | $56.4M | 9.61% | +74.86% |
| Redmile | $47.8M | 8.15% | +24.41% |
| Orbimed | $43.8M | 7.46% | 0.00% |
| Prosight | $41.3M | 7.05% | +19.05% |
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $93.2M | 15.89% | +36.16% |
| Adage Capital Partners GP | $56.4M | 9.61% | +74.86% |
| Redmile | $47.8M | 8.15% | +24.41% |
| Orbimed | $43.8M | 7.46% | 0.00% |
| Prosight | $41.3M | 7.05% | +19.05% |
Largest filed tie
—
Expected move
Inputsspot 5.15exp Mar 19ATM strike 5ATM straddle 4.90IV 215%